Novacyt S.A. (NCYT.L) Notice of investor meeting

Paris, France and Camberley, UK – 5 August 2021 – Novacyt ( EURONEXT GROWTH: ALNOV; AIM: NCYT ), a leading international specialist in clinical diagnostics, announces that it will hold an investor meeting on Wednesday, 18 August 2021, at 13:00 BST / 14:00 CEST.

Novacyt will host a presentation and Q&A session, delivered by various members of the Executive Management Team. No new trading information will be disclosed during the presentation which will focus on providing further background on the Company’s operations and growth strategy, as updated in the announcement on 22 June 2021.

The presentation will be hosted through the digital online platform, Investor Meet Company, with dial-in details also available for attendees once registered.

Investors already registered to the platform and added to meet the Company will automatically be invited. If new to the platform, investors and analysts can sign up to Investor Meet Company for free and add to meet Novacyt via the following link:

Questions can be submitted pre-event via the Investor Meet Company dashboard up until 09:00 BST / 10:00 CEST the day before the meeting. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.


Novacyt SA

Graham Mullis, Chief Executive Officer

James McCarthy, Chief Financial Officer

+44 (0)1276 600081

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company’s lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.